Next Article in Journal
The Intrinsically Disordered N Terminus in Atg12 from Yeast Is Necessary for the Functional Structure of the Protein
Next Article in Special Issue
Characterization of Potential Melanoma Predisposition Genes in High-Risk Brazilian Patients
Previous Article in Journal
Integrated Metabolome and Transcriptome Analysis of Petal Anthocyanin Accumulation Mechanism in Gloriosa superba ‘Rothschildiana’ during Different Flower Development Stages
Previous Article in Special Issue
Deciphering the Functional Status of Breast Cancers through the Analysis of Their Extracellular Vesicles
 
 
Article
Peer-Review Record

The Clinical and Molecular Profile of Lung Cancer Patients Harboring the TP53 R337H Germline Variant in a Brazilian Cancer Center: The Possible Mechanism of Carcinogenesis

Int. J. Mol. Sci. 2023, 24(20), 15035; https://doi.org/10.3390/ijms242015035
by Carlos D. H. Lopes 1,*, Fernanda F. Antonacio 1, Priscila M. G. Moraes 1, Paula F. Asprino 1, Pedro A. F. Galante 1, Denis L. Jardim 1,2, Mariana P. de Macedo 1, Renata L. Sandoval 1, Artur Katz 1, Gilberto de Castro, Jr. 1 and Maria Isabel Achatz 1,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2023, 24(20), 15035; https://doi.org/10.3390/ijms242015035
Submission received: 30 August 2023 / Revised: 17 September 2023 / Accepted: 19 September 2023 / Published: 10 October 2023
(This article belongs to the Special Issue State-of-the-Art Molecular Oncology in Brazil 2.0)

Round 1

Reviewer 1 Report

This paper by Lopes et al. describes the TP53 founder variant R337H in a Brazilian subpopulation. The present paper is in good standing, but my opinion is that it requires several changes and improvements before it can be considered for publication.

1. First and foremost, it would be better if Table 1 contained only clinical data. I would be pro for a new table regarding the mutational status. Data should be better organized in general, as for the reader to get a faster and more comprehensive view upon this re-organized data.

2. Regarding Figure 2, 'Not avaluated' should read 'Not evaluated'. I suggest changing the patterns for the EGFR mutations, as the current patterns seem misleading.

3. Line 104 - not only early stage but locally advanced as well?

4. Figure 4 legend should be amended, as the alphabetic numbering is off.

5. I would critically re-check figure 6b.

6. Lines 220-221 first and third generation of EGFR inhibitors

7. Another limitation that is worth mentioning - the variable time spent by the patients in this media (with increased PM2.5 values), as some may have spent only a limited amount of time compared to others.

8. I consider that the Methods section should be improved.

9. I would also like the authors to improve the concluding remarks.

10. A re-check of the English with slight improvements is expected.

A re-check of the English with slight improvements is expected.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

Please find my comments in the attachment.

Comments for author File: Comments.pdf

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Back to TopTop